Novo Nordisk trims price for blockbuster obesity drug as competition heats up
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Buy the dip in this major pharma stock - Citi
May 6, 2024 9:30 AM EDTCiti analysts said in a note Monday that they believe history shows the dip in one major pharmaceutical company's shares should be bought.
The investment bank said Novo Nordisk (NYSE: NVO) remains Buy-rated, while the firm also maintained a Dkr975.00 price target on the stock.... More
BofA Securities Comments on Novo Nordisk (NVO)
May 3, 2024 5:55 AM EDTBofA Securities analyst Sachin Jain reiterated a Buy rating and $147.00 price target on Novo Nordisk (NYSE: NVO)
The analyst comments "Key takes from 1Q results: 1) 1Q24 adjusted EPS DKK5.68 +29%, 8% ahead of consensus, on 2% sales beat and operating margin 300bps ahead, mainly on S&D, offset by lower OOI (-DKK568m vs +DKK33m,... More
Novo Nordisk (NVO) sales jump on strong demand for obesity drug
May 2, 2024 6:23 AM EDTNovo Nordisk (NYSE: NVO) reported a robust first quarter with a 24% increase in sales at constant exchange rates (CER), reaching DKK 65.35 billion. The company's operating profit also saw a significant rise, jumping by 30% at CER to DKK 31.8 billion. Despite these strong results, shares of the pharmaceutical giant fell by 2.83%.
The first quarter's performance was marked by a notable 34% sales increase in North America Operations, with a 35% increase at CER. This growth was largely attributed to adjustments in gross-to-net sales from previous years. International Operations also saw an 11% rise at CER. Within the... More
